SD-OCT produces higher resolution images of choroidal osteoma

Article

Spectral domain-optical coherence tomography (SD-OCT) produces deeper and higher resolution images of choroidal osteoma than time domain-OCT.

Spectral domain-optical coherence tomography (SD-OCT) produces deeper and higher resolution images of choroidal osteoma than time domain-OCT, claims a study in the British Journal of Ophthalmology.

Dr Paul T. Finger et al., The New York Eye Cancer Centre, New York, USA, compiled a retrospective chart review of 11 patients with choroidal osteoma. The imaging included patient, clinical ultrasonographic, photographic and SD-OCT. Statistical analysis was used to measure basal diameters of tumours taken from fundus photographs and ultrasound images.

In two patients SD-OCT hyporeflective tumours were found, in seven patients the tumours were isoreflective and in two patients the tumours were hyper-reflective. In four patients the intrinsic reflectivity of the tumour was inhomogeneous.

The retina presented with degenerative changes in five patients and the tumour compressed the overlying choroid in eight patients. The study could provide new developments into choroidal osteoma's pathophysiology and diagnosis.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.